Abstract
MicroRNAs (miRNAs) are endogenous small noncoding RNAs that fine-tune cellular gene expression. There is compelling evidence showing that miRNAs can control immune cell development and regulate innate and adaptive immunity in physiological and pathological conditions. Abnormal miRNA expression occurs in many autoimmune diseases, including systemic lupus erythematosus (SLE). Many dysregulated miRNAs are involved in the immune abnormalities and major organ damage in SLE. Studies of miRNA expression in peripheral blood cells, body fluid, and target tissues of SLE patients have revealed unique miRNA signatures of SLE and its associated organ damage. These findings suggest that miRNAs could be used as specific biomarkers for diagnosing SLE and assessing disease activity. Here, we review our current knowledge about the cellular and molecular mechanisms that are possibly used by miRNAs in the pathogenesis of SLE, and the future applications of miRNAs as therapeutic targets in the management of SLE.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
